Huntington’s disease (HD) is an autosomal dominant, neurodegenerative disease characterized by progressive chorea, dystonia, and cognitive decline. Current treatment is entirely focused on symptom management, and includes a cocktail of antidepressants, antipsychotics, and antiepileptics to control patients’ cognitive, behavioral, and neurological symptoms. Treatment for chorea is limited to tetrabenazine and Teva’s Austedo (deutetrabenazine), which launched in 2017. Although new HD treatments are an area of significant unmet need, the recent discontinuation of Teva’s pridopidine has left the late-stage pipeline devoid of candidates. However, the Phase II pipeline includes a variety of symptom-targeting and potential disease-modifying therapies, which could capitalize on the significant commercial opportunity that exists if they can demonstrate efficacy in HD patients.
QuestionsAnswered
How large is the diagnosed prevalent HD population in the United States and EU5, and how will it evolve through 2027?
What impact has the launch of Teva’s Austedo had on the HD treatment algorithm?
Which emerging therapies do neurologists consider the most promising for HD? Which are likely to launch by 2027?
What are the drivers and constraints in the HD drug market and how might these influence emerging therapy uptake?
Product Description
Niche & Rare Disease Landscape & Forecast: comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.